This National Patient Safety Alert requires action to prevent delays in the administration of rasburicase for tumour lysis syndrome (TLS). TLS is a life-threatening emergency that can develop when cancer cells break down rapidly, releasing harmful substances into the bloodstream. It requires urgent treatment with rasburicase in high-risk cases.

The alert requires NHS organisations providing emergency departments and cancer services to complete specific actions within 6 months, including updating risk assessment protocols, ensuring medication availability, and addressing operational barriers to timely treatment.